Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis

An aerosol form of aztreonam lysinate has recently been developed as a treatment for cystic fibrosis patients suffering from chronic Pseudomonas aeruginosa lung colonization. Local administration means the drug can reach mucus concentrations in the order of hundreds of times the MIC 50 of Pseudomona...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Expert review of anti-infective therapy Ročník 9; číslo 11; s. 967 - 973
Hlavní autor:	Assael, Baroukh Maurice
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Taylor & Francis 01.11.2011 Expert Reviews Ltd Informa Healthcare
Témata:	Administration, Inhalation Adolescent Adult aerosol Aerosols Anti-Bacterial Agents - pharmacokinetics Anti-Bacterial Agents - therapeutic use Antibiotics Aztreonam Aztreonam - pharmacokinetics Aztreonam - therapeutic use Bacterial Load Care and treatment Child Chronic Disease Chronic infection Clinical trials Colonization Cystic fibrosis Cystic Fibrosis - complications Cystic Fibrosis - physiopathology Drug Administration Schedule Drug Dosage Calculations Drugs Fibrosis Health aspects Humans Inhalation inhaled antibiotics Lung - drug effects Lung - microbiology Lung - physiopathology Lung diseases Mucus Nebulizers and Vaporizers Pseudomonas aeruginosa Pseudomonas aeruginosa - drug effects Pseudomonas aeruginosa - physiology Pseudomonas Infections - complications Pseudomonas Infections - drug therapy Pseudomonas Infections - microbiology Pseudomonas Infections - physiopathology Randomized Controlled Trials as Topic Respiratory tract Respiratory tract diseases Treatment Outcome
ISSN:	1478-7210, 1744-8336, 1744-8336
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	An aerosol form of aztreonam lysinate has recently been developed as a treatment for cystic fibrosis patients suffering from chronic Pseudomonas aeruginosa lung colonization. Local administration means the drug can reach mucus concentrations in the order of hundreds of times the MIC 50 of Pseudomonas associated with severe lung disease in cystic fibrosis, resulting in a significant reduction in airway bacterial density and a parallel improvement in lung function. These advantages are maintained over prolonged periods of treatments. Administration of the drug is optimized by the use of a specific eFlow ® system, resulting in considerable reductions in treatment times when compared with conventional nebulizers. The drug has been proven safe and no concomitant induction of resistance to Pseudomonas was found during the clinical trial period of 18 months. Aztreonam lysinate has been shown to ameliorate pulmonary function in cystic fibrosis patients with chronic airway Pseudomonas infection and this is paralleled by a reduction in bacterial density in the lungs. The increased availability of new aerosolized antibiotics for cystic fibrosis will lead to new scenarios in the treatment of the disease.
Bibliografie:	ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Undefined-1 ObjectType-Feature-3 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Review-3
ISSN:	1478-7210 1744-8336 1744-8336
DOI:	10.1586/eri.11.131